Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2002
01/03/2002US20020002204 Blowing nitrogen gas through a hollow cylinder of an oxygen permeable plastic, molding the hollow cylinder into an oxygen permeable container, filling the container with aqueous albuterol or salt free of albuterol aldehyde and oxygen
01/03/2002US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging)
01/03/2002US20020002202 L-carnitine fumarate or alkanoyl L- carnitine fumarate is useful for reducing, in a broad range of users and/or patients, the risk of onset of organ ishcemia, and for preventing and/or therapeutically treating it
01/03/2002US20020002201 Administering to a mammal a therapeutically effective amount of 4-ethylamino-2-butynyl cyclohexyl-phenylglycolate and/ or one or more optically active isomers, and salts to treat disorders involving the urethrogenital tract
01/03/2002US20020002200 Novel diphenylethylene compounds
01/03/2002US20020002198 Growth hormone (GH) release in vertebrates may be augmented by an oral dietary supplement composed of acetyl-l-carnitine and an amino acid selected from l-ornithine, l-lysine, l-arginine, l-histidine, l-valine, l-phenylalanine, l-leucine etc
01/03/2002US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation
01/03/2002US20020002196 Administering a patient an effective amount of hydroxyeicosatetraenoic acid related compounds to treat the dry eye
01/03/2002US20020002194 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
01/03/2002US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
01/03/2002US20020002190 Antidiabetic agents increasing the expression of glucokinase (GK) to improve glucose tolerance; increase in glucose exposure coupled through GK in beta-cells to increase insulin secretion and in hepatocytes to increase glycogen deposition
01/03/2002US20020002189 Nicotine therapy method and oral carrier for assuaging tobacco-addiction
01/03/2002US20020002186 Pharmaceutical composition
01/03/2002US20020002185 Compositions and methods for reducing ocular hypertension
01/03/2002US20020002184 Novel process and compound
01/03/2002US20020002183 Benzamides and related inhibitors of factor Xa
01/03/2002US20020002182 Cis-substituted aminocyclopropane derivatives
01/03/2002US20020002181 Use of leptin antagonists for the treatment of diabetes
01/03/2002US20020002180 A synergistic mixture of lamivudine and BMS-200475 for the treatment of a Hepititis B viral infection; effective against mutants resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the HBV
01/03/2002US20020002179 Terazosin in the chronic treatment of the urinary symptoms associated with benign prostatic hyperplasia
01/03/2002US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides
01/03/2002US20020002176 Apomorphine and norapomorphine N-glucuronides, O-sulfates, O-glucuronides, N-sulfates, O-phosphates and N-phosphates, esters, ethers, and N-alkyls; sexual disorders and Parkinson's disease; bioavailability; side effect reduction
01/03/2002US20020002175 Nasal delivery of apomorphine in combination with glycol derivatives
01/03/2002US20020002174 Serotonin antagonists
01/03/2002US20020002173 E. g., 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno-(2,3-d)(1,3)oxazine-2 -one; agonists and antagonists of the progesterone receptor; inducing contraception and treating or preventing benign or malignant neoplastic diseases
01/03/2002US20020002172 Pharmaceutical formulations
01/03/2002US20020002171 Materials and methods for killing nematodes and nematode eggs
01/03/2002US20020002170 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation
01/03/2002US20020002169 Protein kinase inhibitors
01/03/2002US20020002168 Heterocyclic carboxamides
01/03/2002US20020002166 Use of MKC-442 in combination with other antiviral agents
01/03/2002US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis
01/03/2002US20020002164 Morpholine and thiomorpholine tachykinin receptor antagonists
01/03/2002US20020002163 1,4-benzodiazepinones and their uses as CCK antagonists
01/03/2002US20020002162 Synergistic methods and compositions for treating cancer
01/03/2002US20020002161 5-HT ligands used to treat central nervous system disorders
01/03/2002US20020002160 Process for formulation of antibiotic compounds
01/03/2002US20020002159 Use of beta-lactamase inhibitors as neuroprotectants
01/03/2002US20020002158 Potentiation of glutamate receptor function; treating central nervous system disorders
01/03/2002US20020002157 Salen-metal complexes having superoxide, catalase and/or peroxidase activity to treat or prevent diseases from cell or tissue damage
01/03/2002US20020002156 Androgenic steroid compounds and a method of making and using the same
01/03/2002US20020002155 Glucocorticoids; antiimflammatory and immunosuppressive agents
01/03/2002US20020002154 Method and composition for treatment of inflammatory conditions
01/03/2002US20020002153 Gonadotropin releasing hormone(GnRHa); 17-alpha-estradiol and its chemically modified derivatives, as well as those of 17-beta-estradiol and estriol
01/03/2002US20020002151 Minocycline-containing compositions
01/03/2002US20020002150 Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
01/03/2002US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
01/03/2002US20020002147 Stabilizing amount of magnesium stearate; extended dosage formed by extrusion and spheronization and coated with a seal coating; nucleoside reverse transcriptase inhibitor; treatment of retroviruses, HIV
01/03/2002US20020002146 Compositions and methods for the production of S-adenosylmethionine within the body
01/03/2002US20020002145 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
01/03/2002US20020002144 Contacting acetyl coenzyme A with an alkylating derivative of an acetyl acceptor substrate in the presence of an acetyltransferase; antidepressants, analgesics, antipsychotics
01/03/2002US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
01/03/2002US20020002141 For inhibiting apoptosis or apoptosis-like cell death
01/03/2002US20020002140 Novel bisphosphonates and uses thereof
01/03/2002US20020002139 Administering coniferylaldehyde, caffeic acid ethyl ester, sinapinalcohol, chlorogenic acid, eleutheroside B,B1,E,A, 6,8-dimethoxy-7-hydroxycoumarin, syrinagresinol, for modulating immune system
01/03/2002US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone
01/03/2002US20020002137 Combination of growth hormone secretagogues and antidepressants
01/03/2002US20020002135 Pharmaceutical use
01/03/2002US20020001640 Method for improving bone modeling and chondrocyte functioning in growing canines
01/03/2002US20020001631 Human growth hormone
01/03/2002US20020001629 Pretreatment; inducing stress response
01/03/2002US20020001622 By blending redried corn starch, silica and at least one vitamin in a blender in any order to make a dry, free-flowing powder; economical method
01/03/2002US20020001621 By using a variety of polymers, having varying starting molecular weights, by varying the hold time of the nucleophilic compound/polymer solution; encapsulated active agents
01/03/2002US20020001616 Novel method of treatment
01/03/2002US20020001612 Methods of forming protein-linked lipidic microparticles, and compositions thereof
01/03/2002US20020001611 The latter for stability in aqueous medium, for human consumption
01/03/2002US20020001608 Biodegradable implant precursor
01/03/2002US20020001607 Perfluoroalkane or fluorohydrocarbons deoxygenated which prevents their damage to the retina or intraocular structures; use such as treating ischemic retinal disorders
01/03/2002US20020001598 Pharmaceutical microspheres containing valproic acid for oral administration
01/03/2002US20020001591 Compositions for the delivery of antigens
01/03/2002US20020001574 Inserting a polynucleotide selecated from DNA, RNA containing a viral vector into a vessel having a permeable wall and increasing the permeability of the wall for a time sufficent to allow delivery of the polynucleotide to the muscle cells
01/03/2002US20020001573 Immunostimulator anti-cancer compounds
01/03/2002US20020001567 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
01/03/2002US20020001565 Radioprotective agents
01/03/2002US20020001259 Slider for optical head, method for preparation thereof and recording and/or reproducing apparatus
01/03/2002DE10030891A1 New 3,4-dihydroxybenzyl-substituted carbonic acid derivatives are antioxidants and radical scavengers useful e.g. for preventing skin aging or protecting cosmetic, dermatological or foodstuff compositions against oxidation
01/03/2002DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL
01/03/2002DE10029371A1 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka Heterocyclic Aminoalkylpyridinderivate as psychotropic drugs
01/03/2002DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients
01/03/2002DE10027928A1 Use of fatty acid oligoethylene glycol ester derivatives for treating bacterial infections and as bactericides, preservatives and disinfectants
01/03/2002DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin
01/03/2002CA2417699A1 Helicobacter pylori heptosyl transferase polypeptides
01/03/2002CA2417692A1 Helicobacter dd-heptosyltransferase
01/03/2002CA2417552A1 Compositions and methods for treating females sexual response
01/03/2002CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
01/03/2002CA2414678A1 Anthelmintic agents for preventing parasitic infections in humans and animals iii
01/03/2002CA2414512A1 Novel compounds possessing antibacterial, antifungal or antitumor activity
01/03/2002CA2414409A1 Enhancing therapeutic effectiveness of nitric oxide inhalation
01/03/2002CA2414406A1 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
01/03/2002CA2414401A1 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
01/03/2002CA2414389A1 Methods of treating neutrophil-related diseases with topical anesthetics
01/03/2002CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof
01/03/2002CA2414115A1 Indole derivatives useful for the treatment of cns disorders
01/03/2002CA2414089A1 Improvements in and relating to chromophores
01/03/2002CA2413816A1 Controlled release arginine formulations
01/03/2002CA2413768A1 Pharmaceutical compositions for angiogenic therapy
01/03/2002CA2413752A1 Substituted phthalides as anti-convulsive drugs
01/03/2002CA2413702A1 Carvedilol
01/03/2002CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function
01/03/2002CA2413596A1 Cell lines and cell-based assays for identification of androgen receptor modulators